BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35399501)

  • 21. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
    Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
    Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
    Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
    Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
    Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
    J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
    Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
    Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin.
    Devaiah BN; Case-Borden C; Gegonne A; Hsu CH; Chen Q; Meerzaman D; Dey A; Ozato K; Singer DS
    Nat Struct Mol Biol; 2016 Jun; 23(6):540-8. PubMed ID: 27159561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
    Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
    Front Immunol; 2021; 12():626255. PubMed ID: 33717143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long Noncoding RNA MALAT1 Promotes Laryngocarcinoma Development by Targeting miR-708-5p/BRD4 Axis to Regulate YAP1-Mediated Epithelial-Mesenchymal Transition.
    Wu X; Tan Y; Tang X
    Biomed Res Int; 2022; 2022():8093949. PubMed ID: 35601153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. I-BET726 suppresses human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Liu Z; Li P; Yang YQ; Cai S; Lin X; Chen MB; Guo H
    Cell Death Dis; 2020 May; 11(5):318. PubMed ID: 32371868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
    Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
    Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.
    Takagawa Y; Gen Y; Muramatsu T; Tanimoto K; Inoue J; Harada H; Inazawa J
    Mol Ther; 2020 Jun; 28(6):1494-1505. PubMed ID: 32320642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.
    Decker TM; Kluge M; Krebs S; Shah N; Blum H; Friedel CC; Eick D
    Sci Rep; 2017 May; 7(1):1684. PubMed ID: 28490802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.
    Tonouchi E; Gen Y; Muramatsu T; Hiramoto H; Tanimoto K; Inoue J; Inazawa J
    Sci Rep; 2018 Mar; 8(1):4482. PubMed ID: 29540837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
    Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
    Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p.
    Zheng JF; Guo NH; Zi FM; Cheng J
    Mol Cell Biol; 2020 Jan; 40(3):. PubMed ID: 31712391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
    Fan P; Wang B; Meng Z; Zhao J; Jin X
    Int J Biochem Cell Biol; 2018 Nov; 104():1-8. PubMed ID: 30172011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
    Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.